New approach to bone marrow transplantation found to be a safe and effective cure for sickle cell disease
Scientists seeking to harness the power of the immune system to eradicate brain tumors face two major hurdles: recruiting key immune cells called dendritic cells into areas of the brain where they are not naturally found and helping them recognize tumor cells as targets for attack. Researchers at Cedars-Sinai Medical Center, however, have identified a
Full Post: Gene therapy kills brain tumors through selective recruitment of immune cells
A unique approach to bone marrow transplantation pioneered in part by a Children’s Hospital of Pittsburgh of UPMC physician has proven to be the only safe and effective cure for sickle cell disease, according to a new study.
Lakshmanan Krishnamurti, MD, a pediatric hematologist/oncologist at Children’s Hospital, helped pioneer a form of bone marrow transplantation which relies on reduced-intensity conditioning (RIC). RIC regimens are less toxic to patients and therefore can be offered to patients with severe sickle cell disease because they eliminate life-threatening side effects generally associated with bone marrow transplantation.
In a study published in the November issue of the journal Biology of Blood and Marrow Transplantation , Dr. Krishnamurti and colleagues report that six of seven sickle cell patients who received RIC bone marrow transplants in the last decade now have donor marrow and are free from symptoms of their sickle cell disease. Dr. Krishnamurti led five of the seven transplants in the study.
“Bone marrow transplant is the only known cure for sickle cell disease. But doctors have avoided performing them in these patients because complications from a traditional bone marrow transplant can be life-threatening,” said Dr. Krishnamurti, director of the Sickle Cell Program at Children’s Hospital. “Through the reduced-intensity approach we developed, the potential for complications is dramatically lessened. This study offers hope for a cure to thousands of patients with severe sickle cell disease.”
Traditionally, bone marrow transplants require heavy doses of chemotherapy prior to transplant in order to destroy the recipient’s bone marrow so it will not reject the donated marrow. But with their bone marrow destroyed, transplant recipients become vulnerable to life-threatening complications, a risk viewed as unnecessary because sickle cell disease is not typically immediately life-threatening.
Dr. Krishnamurti was the first physician in the world to perform a reduced-intensity bone marrow transplant in a patient with sickle cell disease while at the University of Minnesota in 1999. He joined Children’s Hospital in 2003 and that year, he performed the region’s first successful bone marrow transplant in a patient with sickle cell disease. Austin Jones, then 5, of Indiana, Pa., underwent an RIC bone marrow transplant Aug. 8, 2003, with donor marrow from his brother, Anthony Jr. Today, Austin, now 10, is free of sickle cell disease.
Biopharmaceutical company Kiadis Pharma announces that it has successfully completed treatment of the last patient on its ATIR phase I/II clinical trial. ATIR, a donor lymphocyte cell based product, is under development to prevent acute Graft versus Host Disease (GvHD) and allow early immune reconstitution following a mismatched bone marrow transplantation. Nineteen end stage
Full Post: Kiadis Pharma announces positive results for ATIR in mismatched bone marrow transplantation
Age alone should not determine whether an older patient with acute myeloid leukemia or myelodysplastic syndrome receives a blood stem cell transplant from a matched donor, researchers of the Center for International Blood and Marrow Transplant Research reported today at the 50th annual meeting of the American Society of Hematology. Patients older than 65 do
Full Post: Age has no impact on survival after bone marrow transplant
Two studies examining the effects of stem cell source and patient age on stem cell transplantation outcomes were explored at a press conference on Sunday, December 7 during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA. Preliminary results from a study examining a specialized technique for increasing the presence
Full Post: Effects of stem cell source and patient age on stem cell transplantation outcomes
Taking blood stem cells collected from an umbilical cord into the lab and expanding their number before transplanting them to replace a patient’s blood supply is as safe as a standard cord blood transplant, researchers reported at the 50th Annual Meeting of the American Society of Hematology. In a first-of-its-kind randomized clinical trial, researchers at
Full Post: Trial shows safety of pre-transplant expansion of umbilical cord blood stem cells
Kiadis Pharma has announced that the U.S. Food and Drug Administration (FDA) has granted its product Reviroc Orphan Drug Designations (ODD) for the treatment of two types of Non-Hodgkin Lymphoma (NHL). One ODD has been granted for diffuse large B-cell lymphoma and the other one for the treatment of follicular lymphoma. Reviroc(TM) is under development
Full Post: Kiadis Pharma receives two orphan drug designations for Reviroc